J3320 Spectinomycin Injection HCPCS Reimbursement

HCPCS Level II code J3320 denotes an injection of spectinomycin dihydrochloride, up to 2 grams. This code captures a parenteral antibiotic administration that may be used in outpatient and acute care settings. Nationally, accurate coding for injectable antibiotics affects claims processing, pharmacy supply management, and clinical documentation consistency.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical use and service settings, as well as payer coverage considerations and common billing elements associated with injectable antibiotic therapies. The publication summarizes typical service lines and sites of care where J3320 is billed, and highlights benchmark topics relevant to coding and reimbursement for parenteral antibiotics.

This resource provides a practical reference for coding staff, clinical billing teams, and policy analysts seeking clarity on the purpose of HCPCS Level II code J3320, expected service contexts, and the payer landscape that commonly adjudicates claims for injectable antibiotic administration. Data not available in the input for specific reimbursement rates, associated taxonomies, and ICD-10 mappings.

Billing Code Overview

HCPCS Level II code J3320 represents an injection of spectinomycin dihydrochloride, up to 2 gm. The service involves administration of an antibiotic agent by injection for indications consistent with spectinomycin use.

Service type: Parenteral antibiotic injection
Typical site of service: Ambulatory clinics, emergency departments, outpatient infusion centers, or other settings where intramuscular or intravenous antibiotic injections are administered

Clinical Context

A 28-year-old patient presents to a primary care or sexual health clinic with acute symptomatic urethritis after exposure to a partner with suspected gonorrhea or mixed sexually transmitted infection. Physical exam shows purulent discharge and dysuria. A clinician assesses the patient, collects NAAT or culture specimens, and determines spectinomycin dihydrochloride is indicated due to documented allergy to cephalosporins or local antimicrobial resistance patterns. The medication is supplied as a single intramuscular injection, prepared by pharmacy or administered at point of care. The workflow includes informed consent, pre-administration assessment (allergy review, vital signs), intramuscular injection (typically gluteal), observation for immediate adverse reaction, and documentation of lot number, dose, and route. Follow-up testing or partner notification is arranged per local public health guidance.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When documentation supports substantially greater effort or complexity for the injection visit (e.g., extensive counseling, complex access issues).
`23`	Unusual anesthesia	Rarely applicable; use if general anesthesia or unusual anesthesia was required for administration.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Primary care clinicians commonly diagnose and treat uncomplicated sexually transmitted infections and administer intramuscular antibiotics.
`208100000X`	Internal Medicine	Internists in outpatient clinics may provide diagnosis and intramuscular therapy for STI management.
`367A00000X`	Emergency Medicine	Emergency clinicians may administer single-dose intramuscular therapy for acute symptomatic infections.
`363L00000X`	Obstetrics & Gynecology	OB/GYNs manage reproductive tract infections and may administer intramuscular antibiotics.
`3336C0002X`	Infectious Disease	Infectious disease specialists advise on resistant infections and alternative agents like spectinomycin.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A54.00`	Gonococcal infection of unspecified site	Gonorrhea is a primary indication for spectinomycin when first-line agents are contraindicated or resistance is present.
`A54.01`	Gonococcal infection of the cervix	Cervical gonococcal infections may be treated with single-dose intramuscular antibiotics in outpatient settings.
`A54.02`	Gonococcal infection of the urethra	Urethritis due to Neisseria gonorrhoeae is a common presentation prompting intramuscular antibiotic therapy.
`A54.03`	Gonococcal infection of the rectum	Extragenital gonococcal infection may require systemic intramuscular therapy.
`N34.1`	Nonspecific urethritis, male	When urethritis is suspected and gonorrhea is a consideration, empiric intramuscular therapy may be administered in select cases.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)	Common code used to report administration of an intramuscular antibiotic such as spectinomycin when separate from drug billing.
`99213`	Office or other outpatient visit, established patient, low to moderate severity	Typical E/M visit code for evaluation and management preceding the decision to administer the injection in an outpatient clinic.
`87800`	Infectious agent antigen detection by immunoassay technique, multiple-step method; e.g., gonorrhea/GC NAATs are billed with different lab codes but this code represents point-of-care antigen tests when applicable	Laboratory testing for suspected pathogens commonly occurs before or alongside treatment decisions.
`87070`	Culture, bacterial; any other source except urine, aerobic, with isolation and presumptive identification of isolates	Microbiologic culture may be used for antimicrobial susceptibility testing guiding use of spectinomycin.
`99070`	Supplies and materials (e.g., devices, drugs, etc.) provided by the physician over and above those usually included with the office visit	Use when the drug or specific supplies for injection are furnished by the clinician and payor requires separate reporting.

OpenPayer

Summary & Overview

HCPCS Level II J3320: Spectinomycin Injection, up to 2 gm